Dongbok Shin

REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.

Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen et al. · Journal of Clinical Oncology · 2018 · 96 citations

Medicine, Oncology, Pharmacotherapy +16

ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).

Se Hoon Park, Dae Young Zang, Boram Han et al. · Journal of Clinical Oncology · 2019 · 79 citations

Medicine, Oncology, Surgery +17

Assessing Concordance With Watson for Oncology, a Cognitive Computing Decision Support System for Colon Cancer Treatment in Korea

Won Suk Lee, Sung‐Min Ahn, Jun‐Won Chung et al. · JCO Clinical Cancer Informatics · 2018 · 70 citations

Medicine, Clinical Sciences, Oncology +17

Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial

Jin Won Kim, Sae Won Han, Ik-Joo Chung et al. · European Journal of Cancer · 2020 · 69 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).

David Cunningham, István Láng, Vito Lorusso et al. · Journal of Clinical Oncology · 2013 · 31 citations

Medicine, Oncology, Pharmacology +11